Myung-Ju Ahn, MD

A broad review on how biomarker testing has impacted the clinical staging and management of non–small cell lung cancer across geographic regions.

Shared insight on how comprehensive biomarker testing should be in non–small cell lung cancer, as well as what may or may not be reimbursed.

Expert oncologists from key Asian countries share guidelines for biomarker testing in their countries and how biomarker testing is being used for non–small cell lung cancer in their region.